Shao-Lee Lin Sells 40,000 Shares of Cue Biopharma (NASDAQ:CUE) Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $27.10, for a total transaction of $1,084,000.00. Following the completion of the sale, the chief executive officer directly owned 724,253 shares of the company’s stock, valued at $19,627,256.30. The trade was a 5.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The shares were sold at an average price of $28.62, for a total value of $522,543.96.

Cue Biopharma Stock Performance

CUE traded up $3.12 on Friday, hitting $34.20. The company had a trading volume of 157,074 shares, compared to its average volume of 195,652. The stock has a fifty day moving average price of $29.50 and a 200-day moving average price of $147.28. Cue Biopharma, Inc. has a 12-month low of $4.97 and a 12-month high of $45.50. The stock has a market capitalization of $143.64 million, a price-to-earnings ratio of -6.12 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings data on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.The firm had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million.

Institutional Investors Weigh In On Cue Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. boosted its holdings in Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after purchasing an additional 73,000 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Cue Biopharma during the 3rd quarter worth approximately $62,000. Stifel Financial Corp raised its position in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after buying an additional 50,000 shares during the period. Texas Capital Bank Wealth Management Services Inc raised its position in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after buying an additional 407,568 shares during the period. Finally, Boothbay Fund Management LLC lifted its holdings in Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after acquiring an additional 93,333 shares during the last quarter. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CUE has been the subject of a number of research analyst reports. Weiss Ratings raised Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Wall Street Zen upgraded Cue Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Cue Biopharma presently has a consensus rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.